High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar

Protease-activated receptor 1 (PAR1) is the prototypical member of a family of G-protein-coupled receptors that mediate cellular responses to thrombin and related proteases. Thrombin irreversibly activates PAR1 by cleaving the amino-terminal exodomain of the receptor, which exposes a tethered peptide ligand that binds the heptahelical bundle of the receptor to affect G-protein activation. Here we report the 2.2-Å-resolution crystal structure of human PAR1 bound to vorapaxar, a PAR1 antagonist. The structure reveals an unusual mode of drug binding that explains how a small molecule binds virtually irreversibly to inhibit receptor activation by the tethered ligand of PAR1. In contrast to deep, solvent-exposed binding pockets observed in other peptide-activated G-protein-coupled receptors, the vorapaxar-binding pocket is superficial but has little surface exposed to the aqueous solvent. Protease-activated receptors are important targets for drug development. The structure reported here will aid the development of improved PAR1 antagonists and the discovery of antagonists to other members of this receptor family.

[1]  V. Cherezov,et al.  Crystallizing membrane proteins using lipidic mesophases , 2009, Nature Protocols.

[2]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[3]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[4]  A. Herz,et al.  Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions. , 1990, Molecular pharmacology.

[5]  R. Dror,et al.  Gaussian split Ewald: A fast Ewald mesh method for molecular simulation. , 2005, The Journal of chemical physics.

[6]  V. Wheaton,et al.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.

[7]  R. Stevens,et al.  Structure of the human k-opioid receptor in complex with JDTic , 2012 .

[8]  Hugh Rosen,et al.  Crystal Structure of a Lipid G Protein–Coupled Receptor , 2012, Science.

[9]  Marjorie M Harding Metal-ligand geometry relevant to proteins and in proteins: sodium and potassium. , 2002, Acta crystallographica. Section D, Biological crystallography.

[10]  B. Kobilka,et al.  Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling. , 1993, The Journal of biological chemistry.

[11]  S. Coughlin,et al.  Protease‐activated receptors in hemostasis, thrombosis and vascular biology , 2005, Journal of thrombosis and haemostasis : JTH.

[12]  J. Welsh,et al.  Determinants of Thrombin Receptor Cleavage. RECEPTOR DOMAINS INVOLVED, SPECIFICITY, AND ROLE OF THE P3 ASPARTATE (*) , 1995, The Journal of Biological Chemistry.

[13]  S. Coughlin,et al.  The Cytoplasmic Tails of Protease-activated Receptor-1 and Substance P Receptor Specify Sorting to Lysosomes versusRecycling* , 1999, The Journal of Biological Chemistry.

[14]  B. Kobilka,et al.  Intracellular targeting and trafficking of thrombin receptors. A novel mechanism for resensitization of a G protein-coupled receptor. , 1994, The Journal of biological chemistry.

[15]  V. Wheaton,et al.  Domains specifying thrombin–receptor interaction , 1991, Nature.

[16]  A. IJzerman,et al.  Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions. , 2000, Biochemical pharmacology.

[17]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[18]  Rob Leurs,et al.  Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. , 2007, Annual review of pharmacology and toxicology.

[19]  J. Chen,et al.  Thrombin receptor activation. Confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative intermolecular liganding mode. , 1994, The Journal of biological chemistry.

[20]  A. Vliet,et al.  Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects , 2011, European Journal of Clinical Pharmacology.

[21]  J. Baleja,et al.  Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. , 2003, Chemistry & biology.

[22]  Aashish Manglik,et al.  Structure of the δ-opioid receptor bound to naltrindole , 2012, Nature.

[23]  S. Coughlin,et al.  Role of the Thrombin Receptor's Cytoplasmic Tail in Intracellular Trafficking , 1996, The Journal of Biological Chemistry.

[24]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[25]  S. Coughlin,et al.  Termination of signaling by protease-activated receptor-1 is linked to lysosomal sorting. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Bertil Hille G protein-coupled receptor , 2009, Scholarpedia.

[27]  Albert C. Pan,et al.  Pathway and mechanism of drug binding to G-protein-coupled receptors , 2011, Proceedings of the National Academy of Sciences.

[28]  C W Turck,et al.  Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. , 1994, Biochemistry.

[29]  M. Fregly,et al.  Sodium and Potassium , 1914, The Dental register.

[30]  K. Lindorff-Larsen,et al.  How robust are protein folding simulations with respect to force field parameterization? , 2011, Biophysical journal.

[31]  C. A. Guyer,et al.  An aspartate conserved among G-protein receptors confers allosteric regulation of alpha 2-adrenergic receptors by sodium. , 1990, The Journal of biological chemistry.

[32]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[33]  F. Cohen,et al.  Mechanisms of Thrombin Receptor Agonist Specificity , 1995, The Journal of Biological Chemistry.

[34]  S. Coughlin,et al.  Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis , 2010, Proceedings of the National Academy of Sciences.

[35]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[36]  Marc P. Bonaca,et al.  Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.

[37]  M. García-López,et al.  Thrombin-activated receptors: promising targets for cancer therapy? , 2010, Current medicinal chemistry.

[38]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[39]  L. Limbird,et al.  The role of a conserved inter-transmembrane domain interface in regulating alpha(2a)-adrenergic receptor conformational stability and cell-surface turnover. , 2001, Molecular pharmacology.

[40]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[41]  C. Esmon,et al.  The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. , 1991, The Journal of biological chemistry.

[42]  K. Neve,et al.  Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. , 2001, Molecular pharmacology.

[43]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[44]  T. Schwartz,et al.  Molecular mechanism of 7TM receptor activation--a global toggle switch model. , 2006, Annual review of pharmacology and toxicology.

[45]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[46]  M. Hollenberg,et al.  Targeting proteinase-activated receptors: therapeutic potential and challenges , 2012, Nature Reviews Drug Discovery.

[47]  R. Scarborough,et al.  Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. , 2000, Molecular pharmacology.

[48]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[49]  J. Kutok,et al.  Identification of a novel thrombin receptor sequence required for activation-dependent responses. , 1994, Blood.

[50]  Alexander D. MacKerell,et al.  Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. , 2010, The journal of physical chemistry. B.

[51]  Gianni De Fabritiis,et al.  Induced Effects of Sodium Ions on Dopaminergic G-Protein Coupled Receptors , 2010, PLoS Comput. Biol..

[52]  C. Turck,et al.  Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface , 1994, Nature.

[53]  S. Coughlin,et al.  Separate Signals for Agonist-independent and Agonist-triggered Trafficking of Protease-activated Receptor 1* , 1998, The Journal of Biological Chemistry.

[54]  Mark E. Tuckerman,et al.  Reversible multiple time scale molecular dynamics , 1992 .

[55]  M. Caffrey Crystallizing membrane proteins for structure determination: use of lipidic mesophases. , 2009, Annual review of biophysics.

[56]  H. Schiöth,et al.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.

[57]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[58]  Alexander D. MacKerell,et al.  Extending the treatment of backbone energetics in protein force fields: Limitations of gas‐phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations , 2004, J. Comput. Chem..

[59]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[60]  K. Fahmy,et al.  Protonation states of membrane-embedded carboxylic acid groups in rhodopsin and metarhodopsin II: a Fourier-transform infrared spectroscopy study of site-directed mutants. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[62]  W. Greenlee,et al.  Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. , 2005, Journal of medicinal chemistry.